XML 68 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2010
cvr
Jun. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Sep. 18, 2023
contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag     Derivative assets(2) Derivative assets(2)  
Number of CVR Series | cvr 4        
Agenus Partnered Program          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Percentage of milestones (as a percent)         50.00%
Agenus Partnered Program | Primordial Genetics          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Number of contracts | contract         2
Transferred over Time | Phase 3 clinical trial          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Gross contract asset   $ 10,000 $ 10,000    
Minimum | Agenus Partnered Program | Discount Rate          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Discount rate (as a percent)   0.13 0.13    
Maximum | Agenus Partnered Program | Discount Rate          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Discount rate (as a percent)   0.25 0.25    
Maximum | Transferred over Time | Development, regulatory, & commercial milestones and tiered royalties          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investments   $ 375,000 $ 375,000    
Metabasis          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Number of CVRs issued per acquiree share | cvr 4        
Number of CVRs issued from each CVR series | cvr 1        
Frequency of cash payments to CVR holders 6 months        
Increase of mark-to-market adjustment of CVR liability   1,100 1,100    
Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investment in Viking common stock   53,010 53,010 $ 32,185  
Derivative asset   54,646 54,646 3,531  
Total assets   263,439 263,439 150,886  
Total liabilities   4,198 4,198 3,198  
Recurring | Short-term investments, excluding Viking          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investments, fair value   155,783 155,783 115,170  
Recurring | Contingent liabilities | CyDex          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent liabilities   264 264 320  
Recurring | Contingent liabilities | Metabasis          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent liabilities   3,934 3,934 2,878  
Recurring | Level 1          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investment in Viking common stock   53,010 53,010 32,185  
Derivative asset   0 0 0  
Total assets   63,117 63,117 39,476  
Total liabilities   0 0 0  
Recurring | Level 1 | Short-term investments, excluding Viking          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investments, fair value   10,107 10,107 7,291  
Recurring | Level 1 | Contingent liabilities | CyDex          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent liabilities   0 0 0  
Recurring | Level 1 | Contingent liabilities | Metabasis          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent liabilities   0 0 0  
Recurring | Level 2          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investment in Viking common stock   0 0 0  
Derivative asset   0 0 0  
Total assets   145,676 145,676 107,879  
Total liabilities   3,934 3,934 2,878  
Recurring | Level 2 | Short-term investments, excluding Viking          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investments, fair value   145,676 145,676 107,879  
Recurring | Level 2 | Contingent liabilities | CyDex          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent liabilities   0 0 0  
Recurring | Level 2 | Contingent liabilities | Metabasis          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent liabilities   3,934 3,934 2,878  
Recurring | Level 3          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investment in Viking common stock   0 0 0  
Derivative asset   54,646 54,646 3,531  
Total assets   54,646 54,646 3,531  
Total liabilities   264 264 320  
Recurring | Level 3 | Short-term investments, excluding Viking          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investments, fair value   0 0 0  
Recurring | Level 3 | Contingent liabilities | CyDex          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent liabilities   264 264 320  
Recurring | Level 3 | Contingent liabilities | Metabasis          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent liabilities   $ 0 $ 0 $ 0